Aetiology and disease severity are among the determinants of quality of life in bronchiectasis
- PMID: 31295770
- DOI: 10.1111/crj.13054
Aetiology and disease severity are among the determinants of quality of life in bronchiectasis
Abstract
Introduction: Quality of life (QoL) is known to be impaired in patients with bronchiectasis, which is generally attributed to exacerbations and chronic pulmonary symptoms. The aim of this study was to determine if aetiology and disease severity are associated with QoL in bronchiectasis.
Methods: We conducted a retrospective analysis of clinical stable patients with bronchiectasis. Diagnostic workup into the aetiology of bronchiectasis was conducted according to the current guidelines. QoL was measured by QoL-B questionnaire (QoL-B), data on sputum microbiology, pulmonary function tests and the disease severity were obtained.
Results: The aetiology of bronchiectasis was investigated in the total of 200 patients. The most commonly identified aetiologies were post-infective (39.5%) and idiopathic (12.5%). Patients with chronic obstructive pulmonary disease (COPD)-related bronchiectasis showed a significant lower QoL (P < .05) as compared to the other aetiologies. In the total population, an increasing disease severity as measured by FACED, E-FACED and the bronchiectasis severity index was correlated with a lower QoL.
Conclusions: Our results showed that QoL in bronchiectasis is related both to aetiology, with worse QoL in COPD-related bronchiectasis, and to disease severity, which suggests more attention in advance for these specific patient groups with bronchiectasis.
Keywords: FACED and E-FACED disease severity score; aetiology of bronchiectasis; bronchiectasis severity index (BSI); quality of life bronchiectasis questionnaire (QoL-B).
© 2019 John Wiley & Sons Ltd.
Similar articles
-
Factors Associated With Quality of Life in Subjects With Stable COPD.Respir Care. 2015 Nov;60(11):1585-91. doi: 10.4187/respcare.03904. Epub 2015 Jul 7. Respir Care. 2015. PMID: 26152471
-
The association between serum albumin/prealbumin level and disease severity in non-CF bronchiectasis.Clin Exp Pharmacol Physiol. 2020 Sep;47(9):1537-1544. doi: 10.1111/1440-1681.13331. Epub 2020 May 25. Clin Exp Pharmacol Physiol. 2020. PMID: 32347970
-
Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis.Chest. 2020 Apr;157(4):815-823. doi: 10.1016/j.chest.2019.10.030. Epub 2019 Nov 12. Chest. 2020. PMID: 31730832 Free PMC article. Clinical Trial.
-
Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials.Expert Rev Respir Med. 2018 Sep;12(9):769-782. doi: 10.1080/17476348.2018.1503540. Epub 2018 Aug 3. Expert Rev Respir Med. 2018. PMID: 30025482 Review.
-
A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis.Chest. 2014 Aug;146(2):437-448. doi: 10.1378/chest.13-1891. Chest. 2014. PMID: 24626872 Review.
Cited by
-
The effect of azithromycin on sputum inflammatory markers in bronchiectasis.BMC Pulm Med. 2023 Apr 29;23(1):151. doi: 10.1186/s12890-023-02444-1. BMC Pulm Med. 2023. PMID: 37118704 Free PMC article.
-
In bronchiectasis, poor physical capacity correlates with poor quality of life.Eur Clin Respir J. 2022 Jun 30;9(1):2095104. doi: 10.1080/20018525.2022.2095104. eCollection 2022. Eur Clin Respir J. 2022. PMID: 35800900 Free PMC article.
-
Chronic Obstructive Pulmonary Disease Is Associated With Decreased Quality of Life in Bronchiectasis Patients: Findings From the KMBARC Registry.Front Med (Lausanne). 2021 Aug 16;8:722124. doi: 10.3389/fmed.2021.722124. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34490307 Free PMC article.
-
Bronchiectasis in renal transplant patients: a cross-sectional study.Eur J Med Res. 2024 Feb 13;29(1):120. doi: 10.1186/s40001-024-01701-1. Eur J Med Res. 2024. PMID: 38350996 Free PMC article.
-
The BATTLE study: Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. Study protocol of a double blind, randomized, placebo-controlled trial: study protocol.Contemp Clin Trials Commun. 2022 Dec 6;30:101045. doi: 10.1016/j.conctc.2022.101045. eCollection 2022 Dec. Contemp Clin Trials Commun. 2022. PMID: 36531900 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources